Author(s): Snow RJ, Abeywardane A, Campbell S, Lord J, Kashem MA,
Abstract Share this page
Abstract Benzimidazole 1 was identified as a selective inhibitor of ITK by high throughput screening. Hit-to-lead studies defined the SAR at all three substituents. Reversing the amide linkage at C6 led to 16, with a fivefold improvement of potency. This enhancement is rationalized by the conformational preference of the substituent. A model for the binding of the benzimidazoles to the ATP-binding site of ITK is proposed.
This article was published in Bioorg Med Chem Lett
and referenced in Journal of Clinical & Cellular Immunology